Baseline patient features for CEA and CAS
Variables | Total (n = 270) | CAS (n = 148) | CEA (n = 122) | P value |
---|---|---|---|---|
Age, mean ± SD | 70.89 ± 12.14 | 73.42 ± 11.75 | 68.36 ± 12.53 | < 0.05 |
Male gender | 208 (77%) | 110 (74%) | 98 (80%) | 0.092 |
Qualifying events | ||||
Amaurosis fugax | 38 (14%) | 23 (16%) | 15 (12%) | 0.586 |
TIA | 138 (51%) | 64 (43%) | 74 (61%) | 0.058 |
Stroke | 22 (8%) | 10 (7%) | 12 (10%) | 0.078 |
Asymptomatic | 72 (27%) | 28(19%) | 44 (36%) | < 0.05 |
Diabetes mellitus | 124 (46%) | 66 (46%) | 58 (48%) | 0.896 |
Hypertension | 186 (69%) | 112 (76%) | 74 (61%) | 0.095 |
Smoker | 179 (66%) | 93 (63%) | 86 (71%) | 0.084 |
CAD | 168 (62%) | 102 (69%) | 66 (54%) | 0.243 |
Previous MI | 94 (35%) | 62 (42%) | 32 (26%) | 0.128 |
Previous CABG | 38 (14%) | 22 (15%) | 16 (13%) | 0.765 |
Previous PTCA | 129 (48%) | 72 (49%) | 57 (47%) | 0.923 |
Atrial fibrillation | 46 (17%) | 27 (18%) | 19 (16%) | 0.856 |
PAD | 38 (14%) | 26 (18%) | 12 (10%) | 0.085 |
COPD | 40 (15%) | 32(22%) | 8 (7%) | < 0.05 |
HDL, mean ± SD (mg/dL) | 36.68 ± 7.84 | 36.28 ± 7.35 | 37.08 ± 8.33 | 0.062 |
LDL, mean ± SD (mg/dL) | 129.02 ± 29.35 | 119.56 ± 28.84 | 138.48 ± 29.86 | < 0.05 |
Triglycerides, mean ± SD | 208.32 ± 103.59 | 204.36 ± 84.42 | 212.28 ± 122.76 | 0.278 |
Creatinine, mean ± SD (mg/dL) | 1.14 ± 0.39 | 1.12 ± 0.46 | 1.16 ± 0.32 | 0.153 |
Glucose, mean ± SD (mg/dL) | 145.38 ± 64.31 | 142.53 ± 62.24 | 148.23 ± 66.38 | 0.385 |
Preprocedural medication | ||||
Aspirin | 227 (84%) | 115 (78%) | 112 (92%) | 0.238 |
Clopidogrel | 178 (66%) | 108 (73%) | 70 (57%) | 0.285 |
Antihypertensive | 186 (69%) | 112 (76%) | 74 (61%) | 0.095 |
Statin | 270 (100%) | 148 (100%) | 122 (100%) | 0.994 |
Significant values are in bold. SD: standard deviation; CAD: coronary artery disease; PTCA: percutaneous transluminal coronary angioplasty; PAD: peripheral artery disease; HDL: high-density lipoprotein
We thank Dr. Izatullah Jalalzai on language editing and improving the article.
OB: Conceptualization, Formal analysis, Data curation, Investigation, Resources, Project administration, Writing—original draft. ESÇ: Conceptualization, Formal analysis, Data curation, Investigation, Methodology, Writing—original draft, Supervision, Project administration. ÜA: Conceptualization, Data curation, Investigation, Resources, Supervision, Writing—original draft. YK: Conceptualization, Data curation, Investigation, Resources, Supervision, Writing—review & editing. UK: Conceptualization, Formal analysis, Data curation, Investigation, Methodology, Resources, Writing—review & editing. AÇ: Conceptualization, Investigation, Methodology, Resources, Supervision, Software, Validation. MHT: Conceptualization, Investigation, Supervision, Visualization, Project administration. All authors read and approved the final version of the manuscript.
The authors declare that they have no conflicts of interest.
The study was carried out according to the Declaration of Helsinki (as amended in 2013) and the approval of the Ethics Committee of the Atatürk University Faculty of Medicine was obtained for this study (B.30.2.ATA.0.01.00/714).
For surgical or interventional procedures, patients’ informed consend was acquired, however, since the study was retrospective and the data were anonymized, informed consent was waived.
Not applicable.
On reasonable request, the corresponding author will provide the data supporting the study’s conclusions.
Not applicable.
© The Author(s) 2023.